Please login to the form below

Not currently logged in
Email:
Password:

AiCuris

This page shows the latest AiCuris news and features for those working in and with pharma, biotech and healthcare.

EC grants MSD’s Prevymis orphan product designation

EC grants MSD’s Prevymis orphan product designation

The treatment - which MSD acquired from German biotech AiCuris - has already been approved for use in the same disease indication for the US last year.

Latest news

More from news
Approximately 1 fully matching, plus 2 partially matching documents found.

Latest Intelligence

  • Pharma deals during October 2012 Pharma deals during October 2012

    $142m upfront payment representing approximately 25 per cent of the consideration is certainly attractive for AiCuris and probably reflects the fact that this drug is for an orphan indication. . ... 587. AiCuris / Merck &Co. Licence. Letermovir (phase

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest appointments

  • TiGenix appoints Dr Marie Paule Richard TiGenix appoints Dr Marie Paule Richard

    She takes on role as chief medical officer and brings experience from Aicuris and Crucell. ... An immunologist with over 25 years of experience in the global biopharmaceutical industry, Richard has previously served as chief medical officer at Aicuris in

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Random42 Scientific Communication

Random42 is the world's leading medical animation company. Over the past 25 years we have produced core digital assets for...

Latest intelligence

AstraZeneca’s oncology renaissance
Susan Galbraith played a key role in restoring AstraZeneca’s place in cancer drug development – she talks about the future of oncology and why there’s more to be done to...
Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...
Combined immunotherapies – potential and pitfalls
‘Combining therapeutic compounds is the first logical step towards better results, namely higher rates of patients responding to treatment, with deeper and more sustained responses’...

Infographics